BrenX Ltd. filed a Form 6-K on November 20, 2026, disclosing a $1,000,000 subsequent funding notice received from Alpha Capital Anstalt under an existing securities purchase agreement, with closing expected on or about the same date.
Key Highlights
- $1,000,000 funding notice: BrenX received the November 2026 Subsequent Funding notice from Alpha Capital Anstalt on November 18, 2026, with closing expected on or about November 20, 2026.
- 1,000 preferred shares issued: The company will issue 1,000 preferred shares at a stated value of $1,000 per share, convertible into ordinary shares at a fixed conversion price of $0.4147 per share.
- 2,411,382 ordinary warrants: Ordinary warrants to purchase 2,411,382 ordinary shares will be issued at an exercise price of $87.36 per share, exercisable upon issuance and expiring five years from the initial exercise date.
- Anti-dilution adjustment triggered: As a result of this tranche's pricing, the conversion price of all previously issued preferred shares under the SPA was adjusted to $0.4147 per share under anti-dilution and ratchet adjustment provisions.
- Post-closing share counts: As of closing, the company reported 3,796,155 ordinary shares and 3,913 preferred shares issued and outstanding.
- Use of proceeds: Net proceeds are designated for general corporate purposes, working capital, and execution of the company's commercial TES projects across Europe, the U.S., and the Middle East.
BrenX November 2026 Tranche Under the Alpha Capital Securities Purchase Agreement
According to the filing, BrenX Ltd. (NASDAQ:BRNX) entered into a securities purchase agreement with Alpha Capital Anstalt on July 25, 2025, as subsequently amended, covering up to an aggregate of $25 million in securities across multiple tranches consisting of preferred shares, pre-funded warrants, and ordinary warrants. The company disclosed that between July 2025 and September 2026 it completed multiple closings under that agreement, including an initial closing on July 28, 2025 and subsequent closings between September 2025 and September 2026.
The November 2026 Subsequent Funding represents an additional tranche under the same agreement. The filing states the company will issue 1,000 preferred shares with a stated value of $1,000 per share, convertible at $0.4147 per ordinary share, alongside ordinary warrants to purchase 2,411,382 ordinary shares at an exercise price of $87.36 per share. The warrants are exercisable upon issuance and will expire five years from the initial exercise date, according to the filing.
The filing further states that the pricing of this tranche triggered anti-dilution and ratchet adjustment provisions in the company's Amended and Restated Articles of Association, resetting the conversion price on all previously issued preferred shares under the SPA to $0.4147. The securities were offered pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D, and the company disclosed it has agreed to file a registration statement with the SEC to register the resale of the underlying ordinary shares.
What Was Disclosed
BrenX Ltd. reported a $1,000,000 subsequent funding notice from Alpha Capital Anstalt on November 18, 2026, triggering issuance of 1,000 preferred shares and warrants for 2,411,382 ordinary shares, and an anti-dilution adjustment of the conversion price to $0.4147 across all outstanding preferred shares.



Please wait processing your request...